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Major adverse cardiovascular eventBackground: The omega-3/omega-6 polyunsaturated fatty acid (PUFA) ratio, particularly the eicosapentaenoic
acid (EPA)/arachidonic acid (AA) ratio, is associated with cardiovascular disease. However, the clinical impact
of omega-9 monounsaturated fatty acids (MUFAs) on cardiovascular disease is not well understood. In this
study, we evaluated whether the PUFA/MUFA ratio, especially the EPA/oleic acid (OA) ratio, predicted clinical out-
comes in patients with coronary artery disease (CAD) who underwent percutaneous coronary intervention (PCI).
Methods: The SHINANO registry was a prospective, observational, multicenter cohort study that enrolled 1923
consecutive patients with CAD. From this registry, we identiﬁed 182 patients for whom fatty acids were measured
on admission and stratiﬁed them according to the median EPA/OA ratio. The primary endpoint was major adverse
cardiovascular events (MACEs), including cardiovascular death, nonfatal myocardial infarction, ischemic stroke,
heart failure, and PCI for a de novo lesion within 1 year.
Results: Patients' mean age was 72 ± 9 years, 24% were women, and 28% had acute coronary syndrome. The
1-year follow-up was completed in 181 patients (99.5%). There were 59 cases of MACE. In the Kaplan–Meier
analysis, the MACE incidence was signiﬁcantly higher in patients with an EPA/OA ratio of ≤0.1169 than
in those with a ratio of ≥0.1170 (39.6% vs. 25.3%, p = 0.041). In a multivariate Cox regression analysis, an EPA/
OA ratio ≥0.1170 was associated with a lower incidence of MACE (hazard ratio, 0.53; 95% conﬁdence interval,
0.31–0.91; p = 0.020).
Conclusions:We demonstrated that the EPA/OA ratio predicted MACE in patients with CADwho underwent PCI.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
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land Ltd. This is an open access articlassociated with decreased mortality related to coronary artery disease
(CAD) [1,2]. In particular, large amounts of eicosapentaenoic acid
(EPA) and/or docosahexaenoic acid (DHA) are reported to decrease
the risk of cardiovascular events and death [3–5].
Omega-9monounsaturated fatty acids (MUFAs) are one type of fatty
acid and are different fromPUFAs on the basis of having only one double
bond. Omega-9MUFAsmust be obtained from food, and oleic acid (OA)
is the major component found in food. Although high-omega-9 MUFA
diets have been reported to have cardioprotective effects in some epide-
miologic studies [6], several meta-analyses and epidemiologic studies
found no signiﬁcant association betweenMUFA and CAD [7–9]. One ex-
perimental study demonstrated that a diet high inMUFA caused athero-
sclerosis equivalent to that observed from diets high in saturated fatty
acids [10]. Few studies have assessed the relationship between the
PUFA/MUFA ratio and cardiovascular events. Thus, the aim of this
study was to evaluate whether the PUFA/MUFA ratio could predict ad-
verse events in patients who underwent percutaneous coronary inter-
vention (PCI).e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Study population
This retrospective cohort analysis used integrated data for the period
from August 2012 to July 2013, obtained from the SHINANO (The
Shinshu ProspectiveMulti-center Analysis for Elderly Patients with Cor-
onary Artery Disease Undergoing Percutaneous Coronary Intervention)
registry. The design of the SHINANO registry has previously been de-
scribed in detail [11]. In brief, the SHINANO registry was a prospective,
multicenter, observational registry of patients undergoing PCI with
any coronary heart disease, including stable angina, ST-segment eleva-
tion myocardial infarction (STEMI), non-STEMI, and unstable angina,
from 16 collaborating hospitals located in the Nagano prefecture in
Japan. It is registered with the University Hospital Medical Information
Network Clinical Trials Registry, as accepted by the International Com-
mittee of Medical Journal Editors (UMIN-ID; 000010070). This registry
had no exclusion criteria and was an all-comer registry. The study pro-
tocol was developed in accordance with the Declaration of Helsinki and
was approved by the ethics committee of each participating hospital. All
patients provided written informed consent before participating in the
study.
From among the 1923 patients registered in the SHINANO registry,
we identiﬁed 182 patients for whom circulating fatty acids were mea-
sured andwho did not take EPA treatment on admission. Clinical events
for patients were retrospectively tracked for 1 year (Fig. 1). The primary
endpoint of this study was the incidence of major adverse cardiovascu-
lar events (MACEs), including cardiovascular death, nonfatalmyocardial
infarction (MI), ischemic stroke, heart failure, and any PCI for 1 year.
2.2. Measurement of fatty acids
Fasting blood samples were collected, and the serum levels of fatty
acids were measured at an external laboratory (SRL Inc., Tokyo,
Japan). We evaluated the levels of omega-3 PUFAs (EPA and DHA),
omega-6 PUFAs (arachidonic acid [AA] and linoleic acid [LA]), and
omega-9 MUFA (oleic acid [OA]) in this study. Plasma was stored at
−20 °Cuntil analysis. Using a screw-capped glass tube, 100 μL of plasma
and 1 μg of C17:0 as an internal standard were mixed with 2 mL of
methanolic 5% hydrochloric acid and tightly capped. After shaking,
the mixture was incubated for 2 h at 100 °C. After cooling to roomFig. 1. Patient ﬂtemperature, the methyl derivatives were extracted twice with 2 mL
of n-hexane, dried under a stream of nitrogen, and ﬁnally dissolved in
1 mL of n-hexane supplemented with 0.05% butylated hydroxytoluene
as an antioxidant. The extract was stored at 120 °C until analysis. The
methylated fatty acids were analyzed using a capillary gas chromato-
graph (QP5050A, Shimadzu, Kyoto, Japan). The concentration of each
fatty acid was expressed as μg/mL. To assess the relationship between
adverse events and the PUFA/MUFA ratios, we calculated the ratios of
omega-3 to omega-6 (EPA/AA and DHA/AA) and the ratio of omega-3
to omega-9 (EPA/OA). All participants were stratiﬁed based on the me-
dian of the serum EPA/AA, DHA/AA, DHA/OA, and EPA/OA ratios.
2.3. Deﬁnitions
Nonfatal MI was deﬁned as a 2-fold or greater increase in creatine
phosphokinase, troponin-T levels ≥0.1 ng/mL, or new Q waves in ≥2
contiguous leads on electrocardiography [12]. Ischemic stroke was
deﬁned as the presence of a new neurological deﬁcit lasting for at
least 24 h with deﬁnite evidence on magnetic resonance imaging or
computed tomography [13]. Heart failure (HF) was based on a previous
diagnosis of HF, history of hospitalization for HF, or current treatment
for HF. Diabetes was deﬁned as HbA1C ≥6.5%, fasting plasma glucose
≥200 mg/dL, or treatment with oral hypoglycemic agents or insulin.
Hypertension was deﬁned as systolic blood pressure (BP) ≥140 mm Hg,
diastolic BP ≥90 mm Hg, or ongoing therapy for hypertension.
Dyslipidemia was deﬁned as a serum total cholesterol concentration
≥220 mm Hg, a low-density lipoprotein cholesterol concentration
≥140 mmHg, or current treatment with lipid-lowering therapy. Chronic
kidney disease (CKD) was deﬁned as an estimated glomerular ﬁltration
rate b60 mL/min/1.73 m2 (calculated using the Modiﬁcation of Diet in
Renal Disease formula) [14]. Left ventricular ejection fraction (LVEF)
was assessed by echocardiography using the Teichholz method, and
LVEF ≤40% indicated left ventricular (LV) systolic dysfunction [15].
2.4. Statistical analysis
Continuous variables are presented as the mean ± standard devia-
tion,whereas dichotomous variables are described as numbers and per-
centage. Differences between the patients in each group according to
the median fatty acid ratios were compared using the chi-squared test
for categorical variables and unpaired Student t-tests or Wilcoxonow chart.
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Meier test was performed to assess the cumulative incidence of MACE
in the overall study population. The log-rank test was used to compare
survival curves. A multivariate Cox regression analysis was performed
to determine the independent predictors of MACE in the study
population. Variables that were signiﬁcantly associated with MACE
in the univariate Cox regression analysis were entered into the multi-
variate model. The variance inﬂation factor (VIF) was used to check
multicollinearity for each variable; none of the VIF values was greater
than 3. A p-value b 0.05 was considered statistically signiﬁcant. Statisti-
cal analysis was performed using the Statistical Package for Social
Sciences version 21 (SPSS Inc., Chicago, IL, USA) software.
3. Results
3.1. Baseline characteristics
Overall, 181 of the 182 patients (99.5%) completed the 1-year
follow-up. The patients' baseline characteristics are shown in Table 1.
The mean age of our cohort was 72 ± 9 years. Among the subjects,Table 1
Baseline characteristics stratiﬁed by the median of eicosapentaenoic acid/oleic acid ratio.
Variables Overall
(n = 182)
Age (yrs) 72 ± 9
Female 44 (24.2%)
Body mass index (kg/m2) 23.6 ± 3.7
Hypertension 138 (75.8%)
Dyslipidemia 114 (62.6%)
Low-density lipoprotein cholesterol (mg/dL) 97.1 ± 34.0
High-density lipoprotein cholesterol (mg/dL) 46.5 ± 13.6
Diabetes mellitus 64 (35.2%)
Hemoglobin A1C (%) 6.2 ± 1.3
Current smoker 86 (47.3%)
Estimated glomerular ﬁltration rate (mL/min/1.73 m2) 59.0 ± 27.8
Hemodialysis 23 (12.6%)
Hemoglobin (g/dL) 13.5 ± 2.1
Left ventricular ejection fraction at discharge (%) 63.6 ± 14.9
Left ventricular dysfunction 14 (7.7%)
Atrial ﬁbrillation 27 (14.8%)
Medical history
History of stroke 16 (8.8%)
History of myocardial infarction 46 (25.3%)
Acute coronary syndrome on admission 50 (27.5%)
Multi-vessel disease 87 (47.8%)
Medication at discharge
Aspirin 180 (98.9%)
Thienopyridines 177 (97.3%)
Statins 145 (79.7%)
Angiotensin-converting enzyme inhibitors 56 (30.8%)
Angiotensin receptor blockers 74 (40.7%)
Beta-blockers 73 (40.1%)
Omega-3 polyunsaturated fatty acid
Eicosapentaenoic acid (EPA) (μg/mL) 76.43 ± 41.93
Docosahexaenoic acid (DHA) (μg/mL) 149.75 ± 44.88
Docosapentaenoic acid (μg/mL) 21.07 ± 8.11
α-Linolenic acid (μg/mL) 24.28 ± 11.67
Omega-6 polyunsaturated fatty acid
Arachidonic acid (AA) (μg/mL) 169.75 ± 48.33
Linoleic acid (μg/mL) 682.85 ± 186.23
γ-Linolenic acid (μg/mL) 8.21 ± 6.54
Dihomo γ-linolenic acid (μg/mL) 34.82 ± 13.94
Docosatetraenoic acid (μg/mL) 3.97 ± 2.19
Omega-9 monounsaturated fatty acid
Oleic acid (μg/mL) 610.80 ± 258.65
Erucic acid (μg/mL) 1.32 ± 0.53
Nervonic acid (μg/mL) 36.40 ± 8.64
Mead acid (μg/mL) 2.02 ± 1.88
Gondoic acid (μg/mL) 5.85 ± 3.38
Eicosapentaenoic acid/arachidonic acid ratio 0.48 ± 0.28
Docosahexaenoic acid/arachidonic acid ratio 0.91 ± 0.28
Data are shown as mean ± SD or as n (%). EPA, eicosapentaenoic acid; OA, oleic acid.24.2% were women, 75.8% had hypertension, 62.6% had dyslipidemia,
35.2% had diabetes mellitus, 12.6% were undergoing hemodialysis,
25.3% had a previous MI, 8.8% had a previous stroke, and 7.7% had LV
dysfunction (LVEF, 63.6± 14.9%).With respect to lesion characteristics,
27.5% had acute coronary syndrome (ACS) and 47.8% had multi-vessel
disease. Patients with low (0.0275–0.1169) EPA/OA ratios were more
likely to be women and were less likely to have been administered
thienopyridines than were patients with high (0.1170–0.5407) EPA/
OA ratios. Patients with high EPA/OA ratios had higher serum EPA and
DHA levels and lower omega-6 PUFA levels than did patients with low
EPA/OA ratios. Regarding omega-9 MUFAs, patients with high EPA/OA
ratios had lower serum OA and mead acid than did patients with low
EPA/OA ratios.
3.2. Incidence of MACE in the overall study population
During the follow-up period, the cumulative incidence of MACE was
32.4% (n=59) for the entire study population,which included one case
of cardiovascular death, four cases of nonfatal MI, two cases of ischemic
stroke, six cases of HF, and 46 cases of any PCI. The incidence of MACELow EPA/OA High EPA/OA p-Value
(n = 91) (n = 91)
71 ± 11 73 ± 9 0.244
28 (30.8%) 16 (17.6%) 0.028
23.7 ± 3.9 23.6 ± 3.6 0.853
68 (74.7%) 70 (76.9%) 0.431
57 (62.6%) 58 (63.7%) 0.561
102.0 ± 39.1 92.2 ± 25.2 0.052
44.9 ± 12.5 48.3 ± 13.7 0.124
35 (38.4%) 29 (31.9%) 0.219
6.3 ± 1.0 6.2 ± 0.9 0.150
38 (41.2%) 48 (52.7%) 0.100
60.7 ± 29.4 57.4 ± 26.2 0.365
11 (12.1%) 12 (13.2%) 0.500
13.7 ± 1.9 13.3 ± 1.7 0.150
64.1 ± 12.4 63.2 ± 13.0 0.604
6 (6.6%) 8 (8.8%) 0.374
10 (10.9%) 17 (18.7%) 0.105
9 (9.9%) 7 (7.7%) 0.397
22 (24.2%) 24 (26.4%) 0.432
28 (30.8%) 22 (24.2%) 0.203
41 (45.1%) 46 (50.5%) 0.276
90 (98.9%) 90 (98.9%) 0.751
86 (94.5%) 91 (100%) 0.030
71 (78.0%) 74 (81.3%) 0.356
25 (27.5%) 31 (34.1%) 0.211
36 (39.6%) 38 (41.8%) 0.440
38 (41.8%) 35 (38.5%) 0.381
53.46 ± 21.98 99.40 ± 42.65 b0.001
140.31 ± 44.54 158.13 ± 43.66 0.005
20.65 ± 8.27 21.50 ± 7.99 0.266
26.92 ± 14.07 26.90 ± 50.51 0.063
178.01 ± 53.35 161.49 ± 42.66 0.018
737.77 ± 223.61 630.93 ± 119.57 0.001
9.79 ± 8.30 6.62 ± 3.48 b0.001
39.24 ± 15.48 30.40 ± 10.58 b0.001
4.84 ± 2.64 3.11 ± 1.08 b0.001
710.74 ± 314.80 510.86 ± 123.47 b0.001
1.39 ± 0.62 1.26 ± 0.41 0.080
36.19 ± 9.18 36.61 ± 8.12 0.446
2.60 ± 2.42 1.44 ± 0.77 b0.001
6.34 ± 4.23 5.37 ± 2.16 0.135
0.31 ± 0.11 0.65 ± 0.30 b0.001
0.82 ± 0.24 1.01 ± 0.27 b0.001
Fig. 2. The incidence of 1-yearmajor adverse cardiovascular events (MACEs) overall and in
the subgroup with a low (≤0.1169) or high (≥0.1170) eicosapentaenoic acid (EPA)/oleic
acid (OA) ratio. The incidence of MACE was signiﬁcantly different between the groups
with low EPA/OA and high EPA/OA ratios (chi-squared test for linear trend p b 0.05).
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ratios than in those who had high (0.1170–0.5407) EPA/OA ratios
(39.6% vs. 25.3%, p = 0.028) (Fig. 2). To assess the relation between
MACE and the EPA/OA ratio, we performed a Kaplan–Meier analysis,
which revealed that patients with low (0.0275–0.1169) EPA/OA ratiosFig. 3.A) The Kaplan–Meier analysis according to the incidence ofMACE and the EPA/OA ratio in
ofMACEwas signiﬁcantly higher compared to thosewhohad a high (≥0.1170) EPA/OA ratio (39
MACE and B) the EPA/AA ratio, C) the DHA/AA ratio, and D) and DHA/OA ratio in the overall stu
Log-rank p= 0.105; 38.5% vs. 26.4%, Log-rank p= 0.116; and 37.4% vs. 27.5%, Log-rank p= 0.1
acid; MACE, major adverse cardiovascular event; OA, oleic acid.had signiﬁcantly higher incidences of MACE compared to patients
with high (0.1170–0.5407) EPA/OA ratios (39.6% vs. 25.3%, Log-rank
p=0.041) (Fig. 3A). On the other hand, therewere no signiﬁcant differ-
ences in the incidence of MACE according to the EPA/AA, DHA/AA, and
DHA/OA ratios (Fig. 3B, C, D).
Multivariate analysiswas performed to identify speciﬁc predictors of
MACE in this study population. After adjusting for sex, multi-vessel dis-
ease, patients with CKD undergoing dialysis, history of HF, and ACS on
admission, a serum EPA/OA ratio ≥0.1170 was signiﬁcantly associated
with MACE (hazard ratio, 0.53; 95% conﬁdence interval, 0.31–0.91; p-
value = 0.020). On the other hand, a serum EPA/AA ratio ≥0.4079 and
a DHA/AA ratio ≥0.9169 were not associated with MACE in the same
multivariate model (Table 2).
4. Discussion
In the present study, we demonstrated that low (0.0275–0.1169)
but not high (0.1170–0.5407) EPA/OA ratios were associated with a sig-
niﬁcantly higher incidence of MACE in patients with CAD. Our results
suggest that the serum EPA/OA ratio could be used to predict the occur-
rence of clinical adverse events in patients undergoing PCI for CAD.
Previous studies have demonstrated that omega-3 PUFA, primarily
derived from ﬁsh oil, has anti-arrhythmic, anti-inﬂammatory, and
anti-lipemic effects, resulting in a signiﬁcant reduction of the incidence
of coronary events [5], total mortality, sudden death [4], and ventricular
arrhythmia [9]. Although high consumption of omega-6 PUFA, largely
linoleic acid, was reported to be associated with lower cardiovascularthe overall study population. In patientswith a low (≤0.1169) EPA/OA ratio, the incidence
.6% vs. 25.3%, Log-rank p=0.041). TheKaplan–Meier analysis according to the incidence of
dy population. None of these ratios were related to the incidence of MACE (38.5% vs. 26.4%,
34, respectively). AA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic
Table 2
Cox proportional regression analysis of major adverse cardiovascular events in the overall study population.
Univariate Cox regression analysis
Variable HR 95% CI p-Value
Age 1.02 0.99–1.05 0.114
Female sex 0.95 0.52–1.73 0.870
Body mass index 0.98 0.92–1.05 0.613
Hemodialysis 2.17 1.17–4.02 0.014
Left ventricular dysfunction 1.48 0.64–3.44 0.364
Multi-vessel disease 2.83 1.64–4.88 b0.001
History of myocardial infarction 0.93 0.51–1.69 0.810
History of heart failure 2.05 1.04–4.05 0.039
Stroke 1.36 0.62–3.00 0.441
Peripheral artery disease 1.10 0.57–2.13 0.767
Atrial ﬁbrillation 1.05 0.52–2.13 0.900
Acute coronary syndrome 1.99 1.18–3.35 0.010
EPA ≥ 68.9 μg/mL 0.76 0.46–1.27 0.298
EPA/AA ≥ 0.4079 0.65 0.39–1.10 0.108
DHA/AA ≥ 0.9169 0.66 0.39–1.11 0.120
DHA/OA ≥ 0.2552 0.68 0.40–1.13 0.138
EPA/OA ≥ 0.1170 0.58 0.35–0.98 0.044
Multivariate Cox regression analysis
Variable HR (95% CI) p-Value HR (95% CI) p-Value HR (96% CI) p-Value HR (95% CI) p-Value
Female 0.87 (0.47–1.61) 0.661 0.97 (0.53–1.77) 0.907 0.97 (0.53–1.77) 0.910 0.82 (0.44–1.52) 0.520
MVD 3.16 (1.80–5.53) b0.001 3.18 (1.81–5.58) 0.021 3.21 (1.83–5.64) b0.001 3.22 (1.84–5.62) b0.001
History of HF 1.37 (0.65–2.87) 0.403 1.39 (0.67–2.89) 0.382 1.63 (0.81–3.28) 0.175 1.59 (0.79–3.21) 0.199
CKD on dialysis 2.25 (1.17–4.33) 0.015 2.16 (1.12–4.17) 0.021 2.13 (1.12–4.04) 0.021 2.23 (1.17–4.23) 0.014
ACS 1.99 (1.17–3.39) 0.011 2.03 (1.19–3.44) 0.009 2.11 (1.24–3.56) 0.006 1.98 (1.17–3.37) 0.011
EPA/AA ≥ 0.4079 0.59 (0.34–1.02) 0.060
DHA/AA ≥ 0.9169 0.61 (0.36–1.05) 0.075
DHA/OA ≥ 0.2552 0.61 (0.36–1.04) 0.070
EPA/OA ≥ 0.1170 0.51 (0.29–0.88) 0.016
AA, arachidonic acid; ACS, acute coronary syndrome; CI, conﬁdence interval; CKD, chronic kidney disease; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; HF, heart failure; HR,
hazard ratio; MVD, multi-vessel disease; OA, oleic acid.
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remain unclear because the results from other cohort or randomized
studies are not consistent [17]. Because linoleic acid endogenously con-
verts to AA and omega-3 PUFAs compete with omega-6 PUFAs for syn-
thesis of eicosanoids, the ratio of omega-3 to omega-6 has been
considered to be a biomarker of biochemical and physiological re-
sponses to stress. In a meta-analysis, a high intake of omega-9 MUFA,
largely oleic acid, was reported to be associated with a lower incidence
of all-cause mortality, cardiovascular mortality, and cardiovascular
events [18]. However, similar to results for omega-6 PUFA, it has also
been reported that a diet high in MUFA caused atherosclerosis in an ex-
perimental study [10]. Moreover, there has been no study that exam-
ined the interaction of PUFAs and MUFAs.
In this study, we demonstrated that the serum EPA/OA ratio could
predict adverse clinical events in patients with CAD who underwent
PCI. On the other hand, the EPA/AA ratio, which has been previously re-
ported to be associated withMACE in patients who underwent PCI [19],
was not associated with adverse clinical events in this population. Our
result may change the concept of the relationship between fatty acids
and adverse clinical events.
Omega-6 PUFAs, particularly AA, produce the eicosanoids that result
in proinﬂammatory, pro-aggregative, and vasoconstrictive effects. Be-
cause CAD has an inﬂammatory component, reducing the omega-6
PUFA AA has been considered to reduce the risk of CAD [20]. However,
the opposite effect of reducing omega-6 PUFAs has been reported. The
American Heart Association Nutrition Committee suggested that a
high intake of omega-6 PUFAs actually reduced the risk for CAD [21].
Ferrucci et al. reported that higher plasma levels of omega-6 PUFAs
were associated with decreased plasma levels of interleukin-6 and the
interleukin-1 receptor antagonist, which are known as serum proin-
ﬂammatorymarkers [22]. Kusumoto et al. reported that AA supplemen-
tation had no effect on any fatty acids and platelet aggregation inhealthy adults [23]. Although the EPA/AA ratio has been reported to
be associated with adverse events in a previous study, these studies in-
cluded ≥80%of patientswithout CAD [5] or only patientswith stable an-
gina [19]. Therefore, because the present study included patients with
any CAD, our results concerning the EPA/AA ratio are not consistent
with results of these previous reports.
In contrast to PUFAs,MUFAs, derived fromolive oil or nuts, are associ-
atedwith a lower incidence of cardiovascular events [24]. However, there
has been no research concerning the effect of MUFAs in populations that
donot typically eat olive oil or nuts. A previousmeta-analysis reported in-
consistent results of MUFAs on cardiovascular events. Chowdhury et al.
demonstrated no signiﬁcant associations between circulating MUFAs
and the risk of CAD [7]. In evaluating the beneﬁcial effect of MUFAs on
health, it might be important to consider the source of the MUFAs, be-
cause the primary sources of MUFAs vary from country to country. In
Western countries, MUFA is supplied by foods of animal origin, while
olive oil or nuts are the major sources in southern European countries.
One report noted that a fat loadprovidedbyolive oil increased the plasma
levels of chylomicron remnants,which are atherogenic lipoproteins, com-
pared to a fat load high in PUFAs [25]. Risk stratiﬁcation using onlyMUFAs
mightmiss patientswith a truly high or low risk of cardiovascular disease.
In assessing the impact of fatty acids on health, we should consider
their balance in patients. The EPA/OA ratio may reﬂect a balance of
PUFAs andMUFAs, and the EPA/OA ratiomay help us to predict adverse
outcomes, instead of measuring all PUFA and MUFA components.
There were several limitations in this study. First, this study was a
retrospective analysis of a prospective cohort study. Second, the sample
size was small, and the incidence of events was low. Finally, the mean
follow-up period was 1 year, and so we could not assess the impact of
the EPA/OA ratio in the long-term. Nevertheless, we believe that the as-
sociation of a low EPA/OA ratio with adverse events is applicable to pa-
tients with any CAD.
6 H. Hioki et al. / IJC Metabolic & Endocrine 10 (2016) 1–65. Conclusion
The current study was the ﬁrst to demonstrate that a high EPA/OA
ratio was associated with a lower incidence of MACE in patients with
CAD who underwent PCI. A study with a longer follow-up and larger
sample size is needed to evaluate the long-term impact of EPA/OA in pa-
tients with CAD further.
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